Month: November 2021
Excerpt from the Press Release: Nov 24 (Reuters) – Johnson & Johnson (JNJ.N) said on Wednesday Canada gave full approval to its single-shot COVID-19 vaccine for people aged 18 years and older, making it the first full approval for the vaccine globally. The vaccine was previously authorised by the country under an interim order. (https://refini.tv/30Zd5TR) Canada, which…
Read More
Excerpt from the Press Release: Whatever happened to Novavax and Sanofi’s COVID-19 vaccines? Many people thought at the beginning of the pandemic that these were the two most likely vaccines to succeed. AUDIE CORNISH, HOST: A new kind of COVID-19 vaccine is about to roll out around the world. It’s called a protein subunit vaccine.…
Read More
Excerpt from the Press Release: COVID-19 vaccination is safe for pregnant women and not associated with higher rates of complications, data released by the UK Health Security Agency showed on Thursday, as officials urged pregnant women to take up the offer of shots. The real-world data from the rollout of COVID-19 vaccines in Britain support other studies around the…
Read More
BioNTech is testing its COVID vaccine against a rapidly spreading variant, the Financial Times said. The B.1.1.529 variant has been detected in South Africa, Botswana, Hong Kong, and Israel. Excerpt from the Press Release: BioNTech said it’s testing the COVID-19 vaccine it developed with Pfizer against the new variant that appears to have emerged in southern Africa, and that it would know in two weeks…
Read More
Excerpt from the Press Release: KENILWORTH, N.J. & MIAMI–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today provided an update on the MOVe-OUT study of molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine for COVID-19. Data are now available from all enrolled participants (n=1433). In this…
Read More
Charity Blood Cancer UK has teamed up with oncology company RareCan to support the organisation’s delivery of clinical trials focussed on the prevention, diagnosis, or treatment of rare cancers. Excerpt from the Press Release: Blood cancer The partnership will see Blood Cancer UK join the charity network GIST Cancer UK as RareCan’s partner. The aim…
Read More
– The potentially first-in-class inhibitor designed to target glutathione peroxidase 4 (GPX4) has the potential to impact approximately 500,000 cancer patients with unmet therapeutic needs – BridgeBio and Helsinn have also established a non-exclusive framework agreement to identify and potentially co-develop and co-commercialize additional small molecule targeted oncology therapies – This framework agreement leverages BridgeBio’s…
Read More
The interventional, multicenter, open-label Phase 2 basket trial will evaluate the safety and efficacy of milademetan in patients with MDM2-amplified advanced solid tumors Excerpt from the Press Release: NEWARK, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) — Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that the first patient…
Read More
SG-5-00455 delivered directly to the gut via engineered L. lactis system restores barrier function and improves mucosal healing in an ulcerative colitis model Company also participates as new Crohn’s & Colitis Foundation Corporate Circle member to support Foundation’s IBD treatment, awareness and patient engagement initiatives Excerpt from the Press Release: BRISBANE, Calif. – November 18,…
Read More Adam Miller, MD, to Serve as Lead Investigator for the First Randomized, Placebo Controlled Trial of CCR5 Antagonists and Statins for Chronic COVID Excerpt from the Press Release: SAN CARLOS, Calif.–(BUSINESS WIRE)–IncellDx’s Chronic COVID Treatment Center (CCTC) (www.covidlonghaulers.com) and ARISE™ MD Integrative Medicine & Surgery announced today a new partnership to evaluate CCR5 antagonists and…
Read More